Corbus Pharmaceuticals Holdings Inc
CRBP
Market Cap$112.95M
Close$
$1.28
86.1% downside
Current Fair Value
86.1% downsideOvervalued by 86.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $112.95 Million |
|---|---|
| Enterprise Value | $100.97 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.68 |
| Beta | 3.12 |
| Outstanding Shares | 12,202,092 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.24 |
|---|---|
| PEG | -1.53 |
| Price to Sales | - |
| Price to Book Ratio | 0.92 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.97 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Corbus Pharmaceuticals Holdings, Inc.
28 employees
CEO: Dr. Yuval Cohen Ph.D. Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid...